Analysts said Nevro’s valuation was “inexpensive,” but the spinal cord stimulation business can benefit from Globus’ scale ...

Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

Medicare may cover the implantation of a spinal cord stimulator as a therapy for chronic intractable pain. Chronic intractable pain refers to persistent pain that doesn’t respond to traditional ...

Nevro NVRO is well-poised for growth in ... However, concerns regarding softness in the spinal cord stimulation (SCS) market and dependence on third-party payers persist. This Zacks Rank #2 ...

Jan. 22, 2015 /PRNewswire/ -- Nevro Corp. (NYSE ... of its Premarket Approval Application (PMA) for the Senza spinal cord stimulation (SCS) system. According to the approvable letter, approval ...

With the help of a new spinal cord stimulator, she has regained movement in her hands and can complete tasks she didn't think she would be able to do again. Since participating in the University ...

The moment Owen is referring to is the rollout of a device called ARC-EX, a spinal cord stimulator developed by ... It's a handheld unit, about the size of an iPad, but thicker in order to support ...

Nevro NVRO recently announced preliminary ... 2024 primarily due to the impact of greater-than-anticipated spinal cord stimulation (SCS) device replacement procedures in the fourth quarter of ...

Nevro's comprehensive HFX™ spinal cord stimulation (SCS) platform includes the Senza ® SCS system and support services for the treatment of chronic pain of the trunk and limb and painful ...

Spinal cord stimulators have become a cornerstone for severe back and ... Boston Scientific, Abbott, LivaNova, NEVRO, and BrainsWay. The Infinity DBS system from Abbott integrates directional leads ...